Recently, China Medical System Holdings Limited (“CMS” or the “Group”) achieved two major honors in the fields of pharmaceutical innovation and the capital market. On September 24, at the 2025 China Healthcare Decision-Makers Conference (2025 CHDC) and the Celebration of Decade-long Achievements in China’s Innovative Drugs in Beijing, CMS was listed in the “Industry-Leading Pharmaceutical Enterprises,” recognized for its differentiated innovative pipelines, outstanding commercialization capabilities, and forward-looking presence in emerging overseas markets. On September 26, at the 2025 Global Commercial Newspaper Economic Forum and the “Golden Kunpeng” China Financial Value Ranking Event held in Hong Kong, CMS was awarded the “Best Listed Company” prize for its proactive transformation breakthroughs, outstanding capital market performance, and excellence in ESG practices.
The “Industry-Leading Pharmaceutical Enterprise” selection is based on full-industry-chain data from PharmCube, assessing companies across multiple dimensions including overall pipeline competitiveness, the clinical and commercial value of core products, and international expansion. It identifies benchmark enterprises that drive innovation as their core engine, address unmet clinical needs as their mission, pursue global competitiveness as their goal, and advance the development and upgrading of China’s innovative drug industry ecosystem. CMS’s inclusion signifies the solid progresses of its three major strategies—“product innovation, commercial model reform, and international expansion.” It also affirms the “New CMS”, positioned as a fully integrated, global innovative pharmaceutical company, has earned the recognition of authoritative industry institutions and experts.
The “Best Listed Company” award evaluates financial performance, corporate governance, ESG and social responsibility, brand value, and market influence. The rigorous review process includes preliminary screening, data collection and verification, expert panel assessment, and final determination by the organizing committee. Winning this prestigious award demonstrates CMS’s comprehensive strength and strong recognition from the capital market.
CMS’s strategic upgrade is steadily delivering results: five marketed innovative drugs are accelerating the realization of commercial value, with another five products under regulatory review for marketing in China, while the differentiated pipelines continue to expand. Dermavon, the Group’s skin health business subsidiary, has submitted its application for a separate listing on the Hong Kong Stock Exchange Main Board, further unlocking its high growth potential. Meanwhile, CMS has successfully completed a secondary listing by way of introduction on the Singapore Exchange, taking its “industrial internationalization” strategy to a new level. With a healthier, more competitive product portfolio and a clearer, more focused business structure, CMS has returned to a trajectory of sustained high growth. Since its listing on the Hong Kong Stock Exchange in September 2010, CMS has consistently upheld a balanced approach to prudent operations and high shareholder returns, maintaining a dividend payout ratio of 40% for 15 consecutive years. By the first half of 2025, cumulative cash dividends reached RMB 9.71 billion, sharing growth benefits with its shareholders.
Looking ahead, CMS will remain firmly committed to its strategy of “product innovation, commercial model reform, and international expansion” to strengthen its growth engine. At the same time, the Group will actively participate in and drive industry upgrading, forging deep connections and empowering pharmaceutical innovation forces to build a collaborative and mutually beneficial pharmaceutical ecosystem. Through these efforts, CMS will continue to contribute Chinese wisdom and strength to advancing human health.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.